Not available
Quote | iCad Inc. (NASDAQ:ICAD)
Last: | $1.20 |
---|---|
Change Percent: | 0.0% |
Open: | $1.22 |
Close: | $1.20 |
High: | $1.23 |
Low: | $1.18 |
Volume: | 140,899 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | iCad Inc. (NASDAQ:ICAD)
NASHUA, N.H., June 26, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, today announced it will highlight new research demonstrating the efficacy of its ProFound AI Risk algorithm in breast cancer risk assessment compa...
2024-06-11 09:45:40 ET Summary Nvidia Corporation is likely approaching peak earnings and revenue due to fall back to earth, has had a spectacular run in the past 18 months. While we are several quarters away from peak earnings, we may be at the peak for the stock price. Nvidia to...
Message Board Posts | iCad Inc. (NASDAQ:ICAD)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $ICAD News Article - iCAD's Breast AI Suite Empowers Customers to Lead the Way in Suppo | whytestocks | investorshangout | 03/23/2023 5:10:52 PM |
Looks like a new 10 year low. | willlbone | investorshub | 03/14/2023 2:07:04 PM |
$iCAD looking forward to the start of quarter | Netcool | investorshub | 01/07/2023 11:35:56 PM |
Insider buying today | dletizia | investorshub | 01/06/2023 1:39:43 AM |
On Dec. 5, U.S. stocks were dragged down | dletizia | investorshub | 12/12/2022 3:00:27 PM |
News, Short Squeeze, Breakout and More Instantly...
NASHUA, N.H., June 26, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, today announced it will highlight new research demonstrating the efficacy of its ProFound AI Risk algorithm in breast cancer risk assessment compa...
NASHUA, N.H., June 04, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, announced today the Company will present at the MedInvest MedTech, AI & Di...